Recent Updates
Recently added Catalysts

Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Oct 23, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment739

FDA Designations

No designations recorded

Clinical trial landscape

Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative · 1 trial · 1 indication

Phase 3 1
NCT01218646Study of Quadrivalent Influenza Vaccine Among AdultsInfluenza
COMPLETED739 Analytics
PHASE3COMPLETED
Study of Quadrivalent Influenza Vaccine Among Adults
InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.
Day 21 post-vaccination

Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \<10.

Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain in Participants Aged 65 Years and Older.
Day 21 post-vaccination

Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \<10.

Geometric Mean Titers Against the Influenza Virus Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines (TIV) in Participants Aged 18 Years or Older
Day 0 and Day 21 post-vaccination

Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \<10.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group 1: Investigational Quadrivalent Influenza VaccineEXPERIMENTALParticipants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
Group 2: Investigational Trivalent Influenza VaccineEXPERIMENTALParticipants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
Group 3: Licensed 2010-2011 Trivalent Influenza VaccineACTIVE_COMPARATORParticipants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
Group 4: Licensed 2010-2011 Trivalent Influenza VaccineACTIVE_COMPARATORParticipants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine

Interventions

NameTypeDescription
Investigational Quadrivalent Inactivated Influenza Vaccine, No PreservativeBIOLOGICAL0.5 mL, Intramuscular
Investigational Trivalent Inactivated Influenza Vaccine, No PreservativeBIOLOGICAL0.5 mL, Intramuscular
Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No PreservativeBIOLOGICAL0.5 mL, Intramuscular
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites12

Inclusion criteria: * Subject is 18 years of age or older on the day of inclusion. * Informed consent form (ICF) has been signed and dated. * Able to attend all scheduled visits and to comply with all trial procedures. * For a woman of childbearing potential, use of an effective method of contracep...

Countries:United States
Unlock Eligibility Criteria